Science Pool

Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801

Evotec SE announced today that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialisation of Evotec’s oncology project EVT801.
Read More

Twitter
LinkedIn
Email
Generated by Feedzy